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Abstract
Background: The long-term effect of weight reduction on skeletal health is not well understood. The purpose of
this study was to examine the impact of an intensive medical weight loss intervention using very low energy diet
(VLED) (~ 800 cal/day) that result in significant changes in body weight, on total body bone mineral density (BMD) over
2 years.
Methods: We examined the impact of VLED-induced weight loss on BMD and FFM (Fat-free Mass) after 3–6 months
and again while in weight maintenance at 2 years in 49 subjects. The effects of absolute and relative rate of weight
reduction assessed by change in weight in kilograms were assessed using general linear modeling, with baseline BMD
(or FFM) as a covariate, and age, sex and changes in body weight as primary model predictors.
Results: At the end of 2 years, the average weight loss was greater for men (weight: 23.51 ± 12.5 kg) than women
(weight: 16.8 ± 19.2 kg) and BMD loss was greater among women (0.03 ± 0.04 g/cm2 vs 0.01 ± 0.04 g/cm2) (all p < 0.05).
After adjusting for baseline BMD, age, and sex, there was a small but significant association between total weight loss
and 2-year BMD (β = − 0.001 g/cm2; p = 0.01). Similarly, there was a significant independent association between total
weight loss and 2-year FFM (β = − 116.5 g; p < 0.01).
Conclusions: Despite significant weight loss with VLED, there was only a small loss is BMD.
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Background
Among Americans aged 20 years and older, the preva-
lence of obesity is approximately 35%. Obesity contrib-
utes to morbidity and mortality [1]. By 2030, the total
healthcare costs attributed to obesity may reach as much
as $957 billion [2]. Despite addressing many of the asso-
ciated co-morbid conditions of obesity, little attention
has been paid to the potentially long-term effects of
weight change on bone health. Although bone loss is
known to occur following bariatric surgeries, little is
known about the effects of diet-induced weight loss, and
specifically weight loss achieved by a very-low energy di-
ets (VLED).
Bone strength adapts to meet demands of musculo-
skeletal loading, and therefore, body weight is one of the
strongest predictors of bone mineral density (BMD) [3].
Mechanical stimulation of bone leads to osteoblast pro-
liferation, and conversely, reduction in mechanical load-
ing can cause an increase in bone turnover [4]. Lean
body mass and fat mass are both independent positive
determinants of bone mass, and although BMD may be
higher among obese individuals, BMD per unit of BMI is
lower and not necessarily protective from the risk of
fractures [5, 6]. Excess weight due to adiposity is detri-
mental to bone, and therefore, obesity itself may predict
fractures [7]. Clinical opinions and research pertaining
to the impact of weight loss on the bone has been incon-
clusive. Short-term, longitudinal studies have shown that
weight loss achieved through energy restriction can re-
sult in an increase in bone turnover that is sustained
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even during weight maintenance [8, 9]. In addition to
BMD, bone turnover markers are thought to predict
fracture risk [10]. The long-term effects of VLED on
BMD and bone turnover markers following weight loss
are yet to be identified.
Very-low energy diets are those that contain ≤800 cal
per day, and provide essential daily nutritional require-
ments. VLEDs have become increasing popular in
medically-supervised weight reduction programs for
short durations (e.g., 8–12 weeks), with typical weight
losses of 1.5–2.5 kg/week, or 18–20% after 8–12 weeks
[11, 12]. When incorporated as part of an intensive, be-
havioral lifestyle program, the majority of VLED induced
weight loss can be sustained long-term [11]. This ap-
proach offers a less costly, less invasive and practical al-
ternative to endoluminal and surgical approaches.
Due to the growing obesity prevalence, dietary strat-
egies that restrict calories have shown utility for improv-
ing metabolic health and health-related quality-of-life
[13]. However, the long-term effect of weight reduction
on skeletal health is not well understood. The primary
objective of our study was to determine the longitudinal
association between VLED-induced weight loss on whole
body BMD. In addition, we examined whether weight
loss influenced an important bone turnover marker.
Methods
Design
We included adults who were enrolled in and completed
a 2-year weight management program. All participants
provided written informed consent and the study proto-
col was reviewed and approved by the University of
Michigan Institutional Review Board. The trial is regis-
tered at Clinicaltrials.gov (NCT02043457). The Univer-
sity of Michigan Weight Management Program
(MWMP) is a 2-year, multidisciplinary, multicomponent,
obesity management program, and has been previously
described in detail [13]. Briefly, participants consume a
VLED in the form of total meal replacements and are
asked to increase physical activity from low to moderate
intensity for 40 min per day. Each meal replacement
shake contained 160 kcal, 14 g of protein, 23 g of carbo-
hydrates and were fortified with calcium, multiple vita-
mins including vitamin D. In addition, all participants
were prescribed a multivitamin and Vitamin D3 2000 IU
daily. After 3 to 6 months, participants were transitioned
to regular foods and asked to increase physical activity
to moderate-vigorous for 40–60 min per day. Thereafter,
the intervention was focused on behavioral and pharma-
cologic strategies to prevent weight regain. An individu-
alized diet plan comprised of approximately 1200–
1800 kcal/day was designed, implemented and titrated to
maintain the individual’s reduced weight. A registered
dietitian evaluated participants weekly for one month
and then monthly for the remainder of the two years.
The physician saw participants monthly for three
months and then every three months for the rest of the
two years. Participants underwent whole body DXA
scanning on a (GE Lunar prodigy Advance; Control ser-
ial number 070401531487; control model number 7635)
by a trained research technician at baseline, after transi-
tion to weight maintenance at approximately 6 months,
and at the end of the 2-year program. In addition, serum
for bone turnover markers was collected to assess the
impact of weight loss on bone resorption.
Study participants
The program was designed for obese (BMI ≥30 kg/m2
[or ≥27 kg/m2 in Asian Americans]) adults ≥18 years of
age. Participants in the program were representative of
the demographic of southeastern Michigan, primarily
Non-Hispanic whites, educated and employed. The
clinic was founded on the principles of the National
Heart Lung and Blood Institute (NHLBI) report that
addressed long-term weight management for obese
individuals (available at https://www.ncbi.nlm.nih.gov/
pubmed/24961824) [14]. Participants were excluded if
they had unstable psychiatric disorders requiring fre-
quent changes in medications, cancer within the last
5 years (other than non-melanomatous skin cancers), ac-
tive gallbladder or chronic kidney disease with eGFR
≤35 ml/min, and/or prior bariatric surgery.
Demographic, clinical and metabolic data were col-
lected and entered into a database. This data included
participant’s anthropometric, co-morbid health condi-
tions, medications, laboratory, biopsychosocial and im-
aging data that was updated after each visit.
Primary outcomes
Morphological Assessment: Whole body BMD, total adi-
posity assessed as total fat mass (FM) and percent body
fat (%BF) were measured by dual-energy X-ray absorpti-
ometry in the Michigan Clinical Research Unit. Deter-
mination of FFM was performed for the whole body as a
part of the DXA scan. DXA allows for precise assess-
ment of FFM, comprised of fat-free soft tissue and
BMD.
Biochemical analyses: Serum cross-linked C-telopeptide
(CTX) was collected at baseline, after weight loss between 3
and 6 months, and at the end of the 2-year program for n =
25 subjects (selected based on available fasting samples). All
blood samples were collected into (2 ml tubes containing
EDTA following a 12 h overnight fast to reduce variation as-
sociated with circadian rhythms and feeding [15]. The tests
were analyzed at the University of Michigan, Michigan Dia-
betes Research Center (MDRC) Chemistry laboratory.
Serum CTX levels were measured by enzyme-linked im-
munosorbent assay (ELISA). CTX assessments were done in
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duplicate and all assays were performed in a single run to
eliminate interassay variability. The detection limits of this
assay were 25–800 ng/ml, and inter and intraassay precision
(Coefficients of variation) for CTX assays were < 15%).
Statistical analysis
Descriptive statistics were used to explore the distribution,
central tendency, and variation of each measurement, with
an emphasis on graphical methods such as histograms,
scatterplots, and boxplots. Descriptive statistics for all
demographic and morphologic characteristics were re-
ported at baseline, after short-term weight loss, and at the
2-year time point, as change from baseline. Multiple linear
regression analyses with post-intervention outcomes as
the dependent variable were used to assess the role of
weight loss on change in total body BMD and FFM. All
models included baseline morphologic characteristics for
muscle, BMD and FFM. For the primary aim, age and
weight loss were included as continuous predictors of
2-year BMD and FFM. Several interaction terms were
tested to determine the mediating effect of age and sex,
on changes in muscle, BMD and FFM. Regression as-
sumptions were checked and appropriate transformations
(e.g., log) performed if necessary.
For the sub-analysis, we used a multiple linear regres-
sion approach to evaluate the association between
changes in body weight, BMD, FFM and changes in
serum CTX. Due to the smaller sample of adults with
complete morphological and serum data (n = 25), models
included only age as a covariate, and a change score for
body weight, BMD, FFM as predictors of change in
serum CTX.
Results
Forty-nine participants completed both the induction
and maintenance phase and had complete DXA scans
available at baseline, at 3–6 months and at the end of
2 years. At the end of two years, all participants had sig-
nificant changes in body weight, mean (− 20.8 ± 11.2 kg),
%FM (− 6.7 ± 6.0%), FFM (− 3.45 ± 3.41 kg,), and BMD
(− 0.02 ± 0.04 g/cm2) (all p < 0.05) Descriptive character-
istics of participants stratified by sex are presented in
Table 1. The decline in BMD was similar for both men
and women; however, a statistically significant loss oc-
curred in BMD among women only.
At two years, the mean weight reduction was greater for
men than women; however, change in absolute BMD was
greater among women (p < 0.05). In multivariable analyses
shown in Table 2, after adjusting for age, sex, and baseline
BMD, we found that the total weight lost at the end of
2 years was associated with a small but statistically signifi-
cant loss in BMD at 2-years. There was a 0.001 g/cm2 de-
crease in 2-year BMD per kilogram weight loss. While
men lost more FM, women lost significantly more %FFM
than men. Figure 1 shows the changes in % body weight,
body fat, BMD and FFM from baseline to 2 years in men
and women. In addition, there was a significant independ-
ent association between total weight lost and 2-year FFM
(β = − 116.5 g; p < 0.01). Figure 2 includes partial residual
scatter plot revealing the correlations between relative
changes in body weight and relative changes in BMD (a)
and FFM (b), controlling for age and sex.
In addition, we evaluated the changes in BMD at the
end of the intensive phase of weight loss (i.e. after 15%
weight loss). There was a small but statistically signifi-
cant loss in BMD among women only (0.02 ± 0.01 g/
cm2; p < 0.001). In both men and women, the loss in
BMD at the end of the intensive phase was significantly
correlated to bone loss at 2 years (r = 0.77; p < 0.01) and
(r = 0.33, p < 0.05) respectively.
In the sub-analyses we evaluated changes in the bone
resorption marker, serum CTX and its independent asso-
ciation with changes in body weight, BMD, FFM and %BF.
After adjusting for age, change in %BF was the only sig-
nificant predictor of changes in serum CTX (β = 23.56 pg/
mL; p = 0.04).
Discussion
In our study, participants were involved in a two-year
weight management program that included a three-month
active weight loss phase utilizing an 800-kcal/day standard
VLED. Our results show that VLED-induced weight loss
can result in a small reduction in total body BMD and FFM
at 2-years. Specifically, we found that for every kilogram of
weight loss there was a 0.001 g/cm2 reduction in BMD and
0.1 kg decrease in FFM at 2-years, after adjusting for age,
sex, and baseline BMD. However, it is important to note
that this loss of BMD and FFM may also arise from natural
consequences of the aging process, as previously described
in numerous studies [16]. Indeed, BMD declined substan-
tially in the late peri-menopause, with an average loss of
0.018–0.010 g/cm2/yr. from the spine and hip (P < 0.001 for
both). In post menopause, rates of loss from the spine and
hip were 0.022 and 0.013 g/cm2/yr. (P < 0.001) [17]. Serum
CTX levels increased following the intensive phase and
remained stable in the maintenance phase. Neither baseline
serum CTX nor changes in CTX levels following weight
loss were associated with bone loss.
The effect of weight loss on the bone has been contro-
versial with inconsistent clinical opinions and research
findings. In the Dubbo Osteoporosis Epidemiologic
study, weight change was found to be an independent
predictor of rate of bone loss [18]. Moderate weight re-
duction (greater than 5%) can negatively influence BMD
especially if achieved purely through calorie restriction
[19, 20]. This was also observed in the LOOK AHEAD
study, and while intensive lifestyle interventions resulted
in better glycemic control and weight loss, a statistically
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significant loss in BMD was noted at the total hip and
femoral neck [21]. The impact of calorie restriction on
BMD is seen in younger individuals as well as premeno-
pausal women therefore suggesting that the mechanism
is not solely related to age and the effects of sex steroids
[22, 23]. In middle-aged individuals, weight variability
has been shown to increase the risk of hip fractures [24].
However, the long-term impact of calorie restriction on
fractures is not known [23, 25]. In recently published
data from the LOOK AHEAD study, long term weight
loss in overweight and obese adults with type 2 diabetes
mellitus was not associated with an increase in overall
risk of fractures but maybe associated with an increased
risk of frailty fractures [26]. A few other studies evaluat-
ing the long-term effects of > 5% weight reduction did
not use severe calorie restricted diets [18, 27, 28]. Due
to significant energy restriction, VLEDs induce greater
weight loss than moderate calorie restricted diets. Citing
the need for further research, a meta-analysis performed
by Zibellini et al., found that low calorie or VLED’s did
not cause a reduction in BMD; however, the majority of
studies evaluating the impact of VLEDs on bone loss
have been limited to one year [25]. In addition, low en-
ergy diets that are supplemented with calcium or high
proteins are known to mitigate the rise in bone turnover
[29]. In our study, although the changes were statistically
significant, the change in BMD was small, and thus may
not necessarily be clinically relevant in the short term,
or with respect to future fracture risk. We postulate that
the loss in BMD was likely attenuated by the macro/
micro-nutrient composition of the meal replacement
and adequate vitamin D and mineral intake and less sed-
entary behavior.
Bariatric surgery remains the most effective form of
treatment for severe obesity and historically, Roux-en-Y
gastric bypass (RYGB) procedure was the most com-
monly performed procedure. Though these surgeries are
very effective, the risk of bone loss associated with gas-
tric bypass surgery is well documented [30–33]. Surgical
procedures are associated with decreases in bone mass
and increases in bone turnover markers [34]. Prospective
studies have shown that bone loss following gastric
Table 2 Multiple regression showing the associations between changes in body weight (primary predictor) and BMD and FFM
at 2-years (dependent variable), after adjustment for age, sex, and baseline values (ANCOVA)
Model Predictor(s) β SE t Pr >│t│ Adjusted R2
BMD at 2 Years 0.88
Intercept −0.084 0.120 −0.680 0.500
Age −0.002 0.001 −2.980 0.005
Sex −0.015 0.014 −1.080 0.285
Baseline BMD 1.155 0.082 14.010 < 0.001
Change in Body Weight −0.001 0.001 −2.460 0.017
FFM at 2 Years 0.94
Intercept 5.790 6.780 0.860 0.397
Age −0.052 0.066 − 0.790 0.435
Sex −2.420 1.880 −1.290 0.205
Baseline FFM 0.950 0.074 12.770 < 0.001
Change in Body Weight −0.117 0.045 −2.620 0.012
Table 1 Morphological characteristics for men and women at baseline and at 2-years
Men (n = 29) Women (n = 20)
Baseline Year 2 Mean Δ Baseline Year 2 Mean Δ
Age (years) 51.59 (6.91) 53.58 (6.89) – 49.30 (7.69) 51.28 (7.70) –
Body Weight (kg) 123.68 (13.58) 102.56 (15.16) 23.51 (12.45)†‡ 104.47 (16.78)* 89.45 (14.10) 16.80 (7.60)†
Body Mass Index (kg∙m− 2) 38.58 (3.86) 31.94 (3.92) 7.39 (3.99)† 39.17 (4.62) 33.53 (3.92) 6.32 (2.74)†
Body Fat (%) 41.79 (4.41) 32.95 (7.22) 8.84 (6.53)†‡ 51.45 (4.39)* 47.88 (5.59) 3.57 (3.29)†
Fat Free Mass (kg) 72.72 (6.95) 69.45 (7.55) 3.27 (4.01)† 51.26 (5.72)* 47.54 (6.07) 3.72 (2.38)†
Bone Mineral Density (g/cm2) 1.37 (0.06) 1.36 (0.09) 0.01 (0.04) 1.27 (0.07)* 1.24 (0.08) 0.03 (0.04)†‡
T-score 1.88 (0.77) 1.72 (1.07) 0.16 (0.56) 1.79 (0.84) 1.47 (0.99) 0.32 (0.53)†
*Significant difference between men and women at baseline (p < 0.05)
†Significant difference within sex from baseline to 2 years (p < 0.05)
‡Significant difference between men and women for absolute changes from baseline to 2 years (p < 0.05)
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bypass preferentially affects the hip [32, 35]. Of the vari-
ous bariatric procedures, sleeve gastrectomy is likely as-
sociated with less bone loss than RYGB although the
studies are small and more data are needed [36]. We
postulate that the derangements in calcium and Vitamin
D absorption are likely to play a greater role in bone loss
after surgical procedures. VLEDs may therefore repre-
sent a safer, non-invasive alternative to weight loss with-
out the negative impact on bone.
Evidence pertaining to the long-term impact of weight
loss on bone turnover is lacking. Some studies have
shown low bone turnover in obesity while others have
contrary findings [37, 38]. Following bariatric surgery,
Balsa et al. showed an increase in bone turnover markers
[39]. In our study, we did not find a correlation between
serum CTX and BMD.
Limitations
In this study, DXA imaging at one year was not avail-
able. With this information, we would have been able to
assess the sequential changes in BMD in individuals
whose weight remained stable and those who experi-
enced weight cycling. In addition, we looked at the total
body BMD rather than routinely used sites to assess fra-
gility such as the lumbar spine, femoral neck or hip, and
this may result in under diagnosis of osteoporosis [40].
Fig. 2 Partial residual scatter plot revealing the correlations between relative changes in body weight and relative changes in BMD (a) and FFM
(b), controlling for age and sex
Fig. 1 Relative change in body weight, body fat, BMD and fat free mass from baseline to 2 years in men and women
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Although the utility of DXA in obese individuals is de-
batable, DXA remains the gold standard and the only
available test for measuring BMD in clinical practice
[41]. In addition, whether changes in total body water
with these diets affects fat and fat-free mass assessments
via DXA remains unclear. Our sample size for subgroup
analyses on bone markers was small, and thus we had to
combine men and women. Future larger studies should
aim to determine the longitudinal, dimorphic patterns of
weight loss and BMD changes, taking into consideration
the mediating influence of serum BTM changes. Lastly,
although moderate intensity and regular physical activity
was prescribed as part of the program, physical activity
and participation was self-reported. Since physical activ-
ity and exercise are linked with bone health, future ef-
forts are certainly needed to determine if objectively
measured exercise during VLED interventions can
ameliorate changes in BMD and FFM. Our future stud-
ies will prospectively evaluate key variable such as go-
nadal status, use of bone altering medications and
physical activity.
Conclusion
Obesity has negative effects on bone metabolism and is
associated with a number of cardio-metabolic conditions
that pose threats to bone health. We have shown abso-
lute weight loss that can impact BMD. Although VLED
can promote significant weight loss the decline in BMD
is minor with unclear clinical applicability and must be
weighed against the myriad of other benefits resulting
from weight loss.
Abbreviations
BMD: Bone Mineral Density; BMI: Body Mass Index; CTX: Serum cross-linked
C-Telopeptide; DXA: Dual X-Ray Absorptiometry; FFM: Fat-Free Mass; FM: Fat
Mass; VLED: Very Low Energy Diets
Acknowledgements
The authors would also like to thank Dr. Henry Bone for his useful feedback
on the manuscript.
Funding
The authors would like to acknowledge the University of Michigan Nutrition
Obesity Research Center (MNORC: Grant Number DK089503) and the Michigan
Center for Diabetes Translational Research (MCDTR: Grant Number P30DK092926)
from the National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.
Additional support was provided by the A. Alfred Taubman Medical Institute
and the Robert C. and Veronica Atkins Foundation.
Dr. Choksi was supported by the Michigan Institute for Clinical & Health
Research (MICHR: Port Grant 2UL1TR000433).
Dr. Peterson is funded by the National Institutes of Health (1KO1 HD074706).
The funders had no role in the design and conduct of the study; the
collection, analysis, and interpretation of the data; or the preparation, review,
or approval of the manuscript.
Availability of data and materials
Please contact author for data requests.
Authors’ contributions
PC: participated in study concept, design, statistical analysis and drafting the
manuscript. AR: participated in study concept, design, statistical analysis and
drafting the manuscript. AK: Helped in drafting the manuscript. NM and KZ:
participated with data collection and reviewed the manuscript. CB and CVP:
participated in its design and coordination and helped to draft the manuscript.
MP: participated in study concept, design, statistical analysis and drafting the
manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All participants provided written informed consent and the study protocol
was reviewed and approved by the University of Michigan Institutional
Review Board. The trial is registered at Clinicaltrials.gov (NCT02043457).
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Internal Medicine, University of Michigan, 24 Frank Lloyd
Wright Dr, Ann Arbor, MI 48106, USA. 2Molecular and Integrative Physiology,
University of Michigan, Ann Arbor, USA. 3Department of Physical Medicine
and Rehabilitation, University of Michigan, Ann Arbor, USA. 4Department of
Nutritional Sciences, University of Michigan, Ann Arbor, USA.
Received: 1 March 2018 Accepted: 30 May 2018
References
1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in
the distribution of body mass index among US adults, 1999-2010. JAMA.
2012;307:491–7.
2. Wang CY, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and
economic burden of the projected obesity trends in the USA and the UK.
Lancet. 2011;378:815–25.
3. Heaney RPAS, Dawson-Highes B. Peak Bone mass. Ost Int. 2000;11:985–1009.
4. Iqbal J, Zaidi M. Molecular regulation of mechanotransduction. Biochem
Biophys Res Commun. 2005;328:751–5.
5. Zaidi M, Buettner C, Sun L, Iqbal J. Minireview: the link between fat and
bone: does mass beget mass? Endocrinology. 2012;153(5):2070–5.
6. Zhu K, Hunter M, James A, Lim EM, Walsh JP. Associations between body
mass index, lean and fat body mass and bone mineral density in middle-
aged Australians: the Busselton healthy ageing study. Bone. 2015;74:146–52.
7. Nielson CM, Srikanth P, Orwoll ES. Obesity and fracture in men and women:
an epidemiologic perspective. J Bone Miner Res. 2012;27:1–10.
8. Hinton PS, LeCheminant JD, Smith BK, Rector RS, Donnelly JE. Weight loss-
induced alterations in serum markers of bone turnover persist during
weight maintenance in obese men and women. J Am Coll Nutr. 2009;28:
565–73.
9. Rector RS, Loethen J, Ruebel M, Thomas TR, Hinton PS. Serum markers of
bone turnover are increased by modest weight loss with or without
weight-bearing exercise in overweight premenopausal women. Appl
Physiol Nutr Metab. 2009;34:933–41.
10. Garnero P, Delmas PD. Contribution of bone mineral density and bone
turnover markers to the estimation of risk of osteoporotic fracture in
postmenopausal women. J Musculoskelet Neuronal Interact. 2004;4:50–63.
11. Anderson JW, Grant L, Gotthelf L, Stifler LT. Weight loss and long-term
follow-up of severely obese individuals treated with an intense behavioral
program. Int J Obes. 2007;31:488–93.
12. Rothberg AE, McEwen LN, Kraftson AT, Neshewat GM, Fowler CE, Burant CF,
Herman WH. The impact of weight loss on health-related quality-of-life:
implications for cost-effectiveness analyses. Qual Life Res. 2014;23:1371–6.
13. Rothberg AE, McEwen LN, Kraftson AT, Fowler CE, Herman WH. Very-low-
energy diet for type 2 diabetes: an underutilized therapy? J Diabetes
Complicat. 2014;28:506–10.
14. Guidelines (2013) for managing overweight and obesity in adults. Preface to
the expert panel report (comprehensive version which includes systematic
Choksi et al. Clinical Diabetes and Endocrinology  (2018) 4:14 Page 6 of 7
evidence review, evidence statements, and recommendations). Obesity
(Silver Spring). 2014;22(Suppl 2):S40.
15. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and
variability. Clin Biochem Rev. 2005;26:97–122.
16. Cauley JA, Danielson ME, Greendale GA, Finkelstein JS, Chang YF, Lo JC,
Crandall CJ, Neer RM, Ruppert K, Meyn L, Prairie BA, Sowers MR. Bone
resorption and fracture across the menopausal transition. the Study of
Women's Health Across the Nation Menopause. 2012;19:1200–7.
17. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B,
Lo JC, Johnston JM, Cauley JA, Danielson ME, Neer RM. Bone mineral
density changes during the menopause transition in a multiethnic cohort of
women. J Clin Endocrinol Metab. 2008;93:861–8.
18. Nguyen TV, Seibel MJ, Eisman JA. Bone loss, physical activity, and weight
change in elderly women: the Dubbo osteoporosis epidemiology study.
J Bone Miner Res. 1998;13:1458–67.
19. Jensen LB, Kollerup G, Quaade F, Sorensen OH. Bone minerals changes in
obese women during a moderate weight loss with and without calcium
supplementation. J Bone Miner Res. 2001;16:141–7.
20. Villareal DT, Fontana L, Weiss EP, Racette SB, Steger-May K, et al. Bone
mineral density response to caloric restriction-induced weight loss or
exercise-induced weight loss: a randomized controlled trial. Arch Intern
Med. 2006;166:2502–10.
21. Schwartz AV, Johnson KC, Kahn SE, Shepherd JA, Nevitt MC, Peters AL,
Walkup MP, Hodges A, Williams CC, Bray GA. Effect of 1 year of an
intentional weight loss intervention on bone mineral density in type 2
diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res.
2012;27:619–27.
22. Hamilton KC, Fisher G, Roy JL, Gower BA, Hunter GR. The effects of weight
loss on relative bone mineral density in premenopausal women. Obesity
(Silver Spring). 2013;21:441–8.
23. Villareal DT, Fontana L, Das SK, Redman L, Smith SR, Saltzman E, Bales C,
Rochon J, Pieper C, Huang M, Lewis M, Schwartz AV, Group CS. Effect of
two-year caloric restriction on bone metabolism and bone mineral density
in non-obese younger adults: a randomized clinical trial. J Bone Miner Res.
2016;31:40–51.
24. Meyer HE, Tverdal A, Selmer R. Weight variability, weight change and the
incidence of hip fracture: a prospective study of 39,000 middle-aged
Norwegians. Osteoporos Int. 1998;8:373–8.
25. Zibellini J, Seimon RV, Lee CM, Gibson AA, Hsu MS, Shapses SA, Nguyen TV,
Sainsbury A. Does diet-induced weight loss lead to bone loss in overweight
or obese adults? A systematic review and meta-analysis of clinical trials.
J Bone Miner Res. 2015;30(12):2168–78.
26. Johnson KC, Bray GA, Cheskin LJ, Clark JM, Egan CM, Foreyt JP, Garcia KR,
Glasser S, Greenway FL, Gregg EW, Hazuda HP, Hergenroeder A, Hill JO,
Horton ES, Jakicic JM, Jeffery RW, Kahn SE, Knowler WC, Lewis CE, Miller M,
Montez MG, Nathan DM, Patricio JL, Peters AL, Pi-Sunyer X, Pownall HJ,
Reboussin D, Redmon JB, Steinberg H, Wadden TA, Wagenknecht LE, Wing
RR, Womack CR, Yanovski SZ, Zhang P, Schwartz AV. The effect of
intentional weight loss on fracture risk in persons with diabetes: results
from the Look AHEAD randomized clinical trial. J Bone Miner Res. 2017;
32(11):2278–87.
27. Ensrud KE, Ewing SK, Stone KL, Cauley JA, Bowman PJ, Cummings SR.
Intentional and unintentional weight loss increase bone loss and hip
fracture risk in older women. J Am Geriatr Soc. 2003;51:1740–7.
28. Sogaard AJ, Meyer HE, Ahmed LA, Jorgensen L, Bjornerem A, Joakimsen RM,
Emaus N. Does recalled dieting increase the risk of non-vertebral
osteoporotic fractures? The Tromso study. Osteoporos Int. 2012;23:2835–45.
29. Redman LM, Rood J, Anton SD, Champagne C, Smith SR, Ravussin E. Calorie
restriction and bone health in young, overweight individuals. Arch Intern
Med. 2008;168:1859–66.
30. Carrasco F, Ruz M, Rojas P, et al. Changes in bone mineral density, body
composition and adiponectin levels in morbidly obese patients after
bariatric surgery. Obese Surg 2009:41–46.
31. Coates PS, Fernstrom JD, Fernstrom MH, Schauer PR, Greenspan SL. Gastric
bypass surgery for morbid obesity leads to an increase in bone turnover
and a decrease in bone mass. J Clin Endocrinol Metab. 2004;89:1061–5.
32. Vilarrasa N, San José P, Garcia I, et al. Evaluation of bone mineral density
loss in morbidly obese women after gastric bypass: 3-year follow-up.
Obes Surg. 2011;21:465–72.
33. von Mach MA, Stoeckli R, Bilz S, Kraenzlin M, Langer I, Keller U. Changes in
bone mineral content after surgical treatment of morbid obesity.
Metabolism. 2004;53:918–21.
34. Rodríguez-Carmona Y, López-Alavez FJ, González-Garay AG, Solís-Galicia C,
Meléndez G, Serralde-Zúñiga AE. Bone mineral density after bariatric
surgery. A systematic review. Int J Surg. 2014;12:976–82.
35. Fleischer J, Stein EM, Bessler M, Della Badia M, Restuccia N, Olivero-Rivera L,
McMahon DJ, Silverberg SJ. The decline in hip bone density after gastric
bypass surgery is associated with extent of weight loss. J Clin Endocrinol
Metab. 2008;93:3735–40.
36. Nogues X, Goday A, Pena MJ, Benaiges D, de Ramon M, Crous X, Vial M,
Pera M, Grande L, Diez-Perez A, Ramon JM. Bone mass loss after sleeve
gastrectomy: a prospective comparative study with gastric bypass. Cir Esp.
2010;88:103–9.
37. Cifuentes M, López-Alavez FJ, Lewis RD et al. Bone turnover and body
weight relationships differ in normal-weight compared to heavier
postmenopausal women. Osteoporos Int. 2003;14(2):116–22.
38. Ostrowska Z, Zwirska-Korczala K, Bunter B et al. Assessment of bone
metabolism in obese women. Endocr Regul 1998; 32.
39. Balsa JA, Botella-Carretero JI, Peromingo R, Caballero C, Munoz-Malo T,
Villafruela JJ, Arrieta F, Zamarron I, Vazquez C. Chronic increase of bone
turnover markers after biliopancreatic diversion is related to secondary
hyperparathyroidism and weight loss. Relation with bone mineral density.
Obes Surg. 2010;20:468–73.
40. Graat-Verboom L, Spruit MA, van den Borne BE, Smeenk FW, Wouters EF.
Whole-body versus local DXA-scan for the diagnosis of osteoporosis in
COPD patients. J Osteoporos. 2010;2010:640878.
41. Yu EW, Thomas BJ, Brown JK, Finkelstein JS. Simulated increases in body fat
and errors in bone mineral density measurements by DXA and QCT. J Bone
Miner Res. 2012;27:119–24.
Choksi et al. Clinical Diabetes and Endocrinology  (2018) 4:14 Page 7 of 7
